Apo-2 receptor
AssigneeGenentech, Inc.
InventorsCamellia W. Adams, Avi J. Ashkenazi, Anan Chuntharapai, Kyung Jin Kim
Life of this patent
Estimating the term…
Abstract
Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
Claims64
Isolated Apo-2 polypeptide having at least 80% amino acid sequence identity with native sequence Apo-2 polypeptide comprising amino acid residues 1 to 411 of SEQ ID NO:1.
Isolated Apo-2 polypeptide comprising amino acid residues 1 to 411 of SEQ ID NO:1.
Isolated extracellular domain sequence of Apo-2 polypeptide comprising amino acid residues 54 to 182 of SEQ ID NO:1.
Isolated death domain sequence of Apo-2 polypeptide comprising amino acid residues 324 to 391 of SEQ ID NO:1.
An Apo-2 polypeptide which is obtained or obtainable by expressing the polypeptide encoded by the cDNA insert in ATCC deposit accession number 209021.
A non-human, transgenic animal which contains cells that express DNA encoding Apo-2 polypeptide.
A non-human, knockout animal which contains cells having an altered gene encoding Apo-2 polypeptide.
An antibody which specifically binds to an Apo-2 polypeptide.
The hybridoma cell line deposited as ATCC accession number HB-12456.
The monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number HB-12456.
A homodimeric molecule comprising a first Apo-2 antibody and a second Apo-2 antibody.
A method of treating mammalian cancer cells comprising exposing mammalian cancer cells to an agent which activates Apo-2.
An article of manufacture comprising a container and a composition contained within said container, wherein the composition includes Apo-2 polypeptide or Apo-2 antibody.
Dependencies are inferred from the claim text.